A patient in Jakarta choosing a hospital in Penang, or a patient in Dhaka choosing between Bangkok and Kuala Lumpur, is making a high-consequence decision with almost none of the informational safeguards they would have at home. They cannot ask a local GP for a referral. They usually cannot read the facility’s regulatory record. They will not meet the surgeon before arrival. And if something goes wrong after they fly home, the clinical and legal follow-up path is unclear.

What they are given instead is marketing. And in Asia’s medical travel market, the volume of marketing has grown considerably faster than the quality of the evidence behind it.

The Market Is Large, Competitive and Loosely Documented

The scale is not in question. The Malaysia Healthcare Travel Council, an agency under the Ministry of Health, reported 1.6 million healthcare travellers in 2024 — a 14 per cent increase year on year — generating RM2.72 billion in revenue, itself 21 per cent above 2023. MHTC has set a target of RM12 billion in industry revenue by 2030 and designated 2026 as the country’s first Malaysia Year of Medical Tourism.

Thailand remains the regional leader by volume, receiving more than a million medical travellers annually. Figures published by Thailand’s Ministry of Tourism and Sports put the country’s broader health tourism industry at 92,813 operators in 2025, generating around THB 670 billion in total revenue across the sector. Singapore continues to compete at the complex, high-acuity end, while India, Vietnam, South Korea and Indonesia are all building or defending positions.

Now look at the same data more closely. Reports of Malaysia’s 2025 performance diverge: healthcare travel revenue of roughly RM3.3 to RM3.35 billion is broadly consistent across sources, but traveller counts for that year have been reported as both approximately 1.6 million and approximately 1.85 million. One published analysis noted that dividing the revenue figure by the lower traveller count implies average hospital receipts of only around RM2,000 per patient — and reasonably asked whether the category is capturing genuine medical travel or a much broader mix that includes day screenings, accompanying persons and routine consultations.

The point is not that anyone is being dishonest. The point is that if a national statistic collected by a government agency can be read two ways because the underlying definition is elastic, a hospital’s own promotional numbers are almost certainly less robust. A market with more than 90,000 operators in one country alone cannot be navigated on reputation and photography.

What Patients Are Actually Deciding Under

The CDC Yellow Book 2026, the standard reference used by clinicians advising international travellers, describes the real decision environment plainly. Patients frequently choose a destination or facility based on cost, availability of a procedure, cultural or language familiarity, and recommendations from friends, family or social media. Infection-related complications are the most common problem among medical travellers, including surgical site and blood-borne infections where infection prevention and control practices are inadequate. And travellers may not have the same legal recourse abroad that they would have at home.

That guidance also makes a point that hospital marketing teams across the region should internalise: accreditation is a statement about process, not a guarantee of outcome. It is meaningful, and its absence is a red flag — but it does not do the work that a lot of medical travel marketing implies it does.

This creates a specific obligation for providers. When the patient cannot verify, the provider must be verifiable.

Three Kinds of Claim, Three Different Evidence Standards

Most credibility failures in medical travel come from collapsing three very different types of statement into one brochure. They are not interchangeable, and they cannot be supported by the same evidence.

Type of claim	Example	What actually substantiates it	Who can verify
Marketing claim	“World-class care in a world-class setting.”	Nothing. It is a positioning statement and carries no evidentiary weight.	No one. It should never be used to answer a clinical question.
Operational or institutional claim	“We treated patients from 34 countries last year.” “Largest dedicated fertility facility in the state.” “50,000 screenings completed under our community programme.”	Auditable internal records, a published counting methodology, a defined time period, and ideally an independent party that has reviewed the documentation.	Auditors, registries, government agencies, or independent record and certification bodies.
Clinical outcome claim	“Higher success rates.” “Lower complication rates than regional peers.”	Risk-adjusted outcome data, a defined comparator population, a stated denominator, and ideally external or peer-reviewed validation.	Clinical registries, regulators, peer review. Nothing else is adequate.

The failure mode is almost always the same: an operational figure is presented in a way that invites a clinical inference. “Asia’s largest cardiac centre” is a facility claim. It is not evidence that a patient’s bypass will go better there. Both statements can be true, but they require entirely separate proof, and a responsible hospital does not let the first quietly stand in for the second.

The Cross-Border Credibility Test

Before any figure appears in an international patient brochure, a country landing page or a facilitator’s deck, the international patient department should be able to answer six questions about it. If any answer is missing, the claim is not ready to travel.

1. Is it specific? A number, a unit and a defined scope — not an adjective.
2. Is the denominator stated? “98 per cent satisfaction” means nothing without knowing how many patients were surveyed, when, and how they were selected.
3. Is the period defined? Cumulative-since-founding and last-financial-year are different claims and should never be presented identically.
4. Could an outsider reproduce it? If your own finance or clinical informatics team could not rebuild the figure from source records, an external reviewer certainly cannot.
5. Is it comparable? If you are claiming a leading position, state against whom, in what geography, and on what measure.
6. Does it stay in its lane? Does the wording, read quickly by an anxious patient, imply a clinical benefit the evidence does not support?

That sixth test is the one most often failed, and it is the one with real patient consequences.

Where Independent Recognition Fits — and Where It Does Not

Question four above is the difficult one, because self-certification is worth very little to a patient who has never heard of your institution. This is where external verification earns its place. Regulatory licensing establishes the floor. International accreditation such as JCI, or national schemes such as Malaysia’s MSQH, verify that systems and processes meet a defined standard. Neither, as noted, speaks to individual outcomes.

A third category sits alongside these and is frequently misunderstood: independent recognition of measurable institutional achievement. Where a hospital group, clinic chain, wellness operator or medical technology company has reached a milestone that is genuinely exceptional in scale — the largest facility of its type in the region, a first-of-its-kind programme, a documented participation or distribution figure — that achievement can be submitted for external review rather than simply announced. Platforms such as the official record listing maintained by Asia Record, which already includes wellness and healthcare-related organisations among its record holders, assess submitted documentation and issue formal record certification in Asia on that basis.

The distinction has to be held firmly. Becoming an Asia Record holder is a form of independent business achievement recognition across Asia. It substantiates that a stated measurement was reviewed against evidence by a third party. It is not, and must never be presented as, evidence that a treatment is more effective, that outcomes are better, or that a patient will be safer. A corporate record in Asia belongs in the institutional and business section of a hospital’s communications, not in a clinical claim. Any organisation that blurs that line has damaged the credibility it was trying to build.

Providers that see a legitimate fit usually arrive at the same practical questions — how to get an Asia Record, what an Asia record application involves, and what documentation the review requires. The published process runs from nomination and submission of supporting documents through an eligibility and judging review to the outcome and formal recognition. The governing principle for a healthcare organisation is straightforward: only apply for Asia Record recognition on a measurement you would be comfortable defending in front of your own clinical governance committee. If a figure cannot survive that room, it should not be submitted anywhere.

A Working Checklist for International Patient Teams

• Publish your methodology, not just your numbers. A short “how we count” note on the international patients page is a stronger trust signal than a bigger figure.
• Separate the pages. Institutional scale and clinical services should not share a paragraph.
• Name the accreditations precisely, with the accrediting body, the scope of accreditation and the current validity period.
• Document the continuity-of-care pathway before marketing the procedure. Who does the patient contact from their home country on day four, day fourteen, day ninety? Given that infection is the most common complication in medical travel, this is a clinical safety matter, not an administrative one.
• Be explicit about jurisdiction. State which country’s law governs the treatment relationship and what the complaints route is. Patients rarely ask. The ones who do are your best-informed prospects.
• Audit your facilitators. Agents and aggregators frequently upgrade a hospital’s claims without permission. Their language becomes your reputation.

Common Mistakes

• Quoting cumulative case volumes in a context that implies annual volume.
• Using patient testimonials in place of outcome data for procedures where outcome data exists.
• Presenting an award — for which the entry criteria are unpublished — as though it were an accreditation.
• Publishing a superlative without a named comparator, geography or date.
• Allowing a marketing agency to write clinical service copy without clinical sign-off.
• Treating any form of recognition, including record recognition in Asia, as a substitute for clinical evidence.

The Business Case for Restraint

There is a commercial argument here, not only an ethical one. Medical travel is a referral-driven market. Indonesian patients travelling to Malaysia, Bangladeshi patients travelling to Kuala Lumpur, Gulf patients travelling to Bangkok — these flows are sustained by families, diaspora networks, employers and insurers who compare experiences. Overstated claims produce a mismatch between expectation and reality that shows up as complaints, refund demands and negative word of mouth in exactly the source markets that took years to develop.

Verifiable, conservatively stated claims do the opposite. They survive scrutiny from an insurer’s medical director, from a corporate health procurement team and from a journalist. As competition intensifies across Southeast Asia — and with Malaysia, Thailand, Singapore, India and Vietnam all investing in the same patient pools — the differentiator will increasingly be which institutions can prove what they say rather than which can say it most loudly.

The hospitals that will hold ground in this market are the ones that treat every external claim as a governance artefact: owned by someone, sourced to a record, reviewed on a schedule, and retired when it stops being true.

This article is intended for healthcare professionals and organisations and is provided for general informational purposes. It does not constitute medical advice and should not be used to make individual treatment or travel decisions. Patients considering treatment abroad should consult a qualified healthcare professional in their home country before travelling.